Related Experiment Videos
[Intravenous-intramuscular bioequivalency of ceftriaxone in newborn infants]
M A Saby1, M Guibert, J F Magny
1Service de Pédiatrie et Réanimation néonatales, Hôpital Antoine-Béclère, Clamart.
Archives Francaises De Pediatrie
|October 1, 1987
Insights
Intravenous and intramuscular ceftriaxone injections are bioequivalent in neonates. A single daily dose achieves effective bacterial serum levels against common secondary infections.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Infectious Diseases
Context:
- Neonates are susceptible to secondary bacterial infections.
- Ceftriaxone is a commonly used antibiotic in neonatal care.
- Understanding optimal drug administration routes is crucial for effective treatment.
Purpose:
- To compare the bioequivalence of intravenous (IV) and intramuscular (IM) ceftriaxone administration in neonates.
- To assess the efficacy of a single daily ceftriaxone injection in achieving therapeutic serum concentrations.
Summary:
- This study compared maximum and residual serum concentrations of ceftriaxone in 6 neonates over the first 7 days of life.
- Both IV and IM administration routes demonstrated bioequivalence.
- A single daily injection of ceftriaxone was sufficient to achieve bactericidal serum levels against most common pathogens responsible for secondary infections in neonates.
Impact:
- Provides evidence supporting the interchangeable use of IV and IM ceftriaxone in neonates.
- Supports the use of a simplified, single daily dosing regimen.
- May improve treatment adherence and reduce healthcare burden in neonatal settings.
Abstract:
In 6 neonates over 7 days of life, comparison of maximum and residual serum concentrations of ceftriaxone after intra-venous or intra-muscular administration showed the bio-equivalence of both ways. In both cases a single daily injection obtained bacterial serum levels on most of the strains responsible for secondary bacterial infections in neonates.